Table 1.
Liposome-based therapies for breast cancer currently in clinical use.
| Product name | Active agent | Approval year | Indication | Description of liposome | Composition | References |
|---|---|---|---|---|---|---|
| Doxil® (US)/Caelyx ® (EU) | DOX HCl | 2003, USA; 2010, EU |
Metastatic breast cancer | PEGylated stealth liposomes,80–90 nm | HSPC, CHOL,DSPE-PEG (2000) | [[74], [75], [76]] |
| Myocet liposomal | DOX | 2000, EU; “Fast Track” status, USA |
HER2+ metastatic breast cancer | Non-PEGylated,150–250 nm | EPC, CHOL | [[77], [78], [79]] |
| Lipodox®a | DOX HCl | 2012, USAb | Breast cancer | PEGylated stealth liposomes, ∼100 nm |
DSPC, CHOL, DSPE-PEG (2000) | [80] |
| Lipusu® | PTX | 2003, China | HER2- metastatic breast cancer | Non-PEGylated,∼400 nm | Not available | [81,82] |
CHOL: cholesterol; DOX: doxorubicin; DSPE-PEG (2000): 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000]; EPC: egg yolk phosphatidylcoline; HCl: hydrochloride; HSPC: hydrogenated soybean phosphatidylcholine.
a
Not to be confused with Lipo-Dox. Lipodox® is manufactured by Sun Pharmaceuticals Industries Ltd. (India) and has been approved by the FDA as a generic equivalent of Doxil® since 2013. Lipo-Dox is manufactured by TTY Biopharm (Taiwan) [83].
b
Substitute during drug shortage [84].